ArticleDermatologic therapy2022
Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases.
Article in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pooled it
- Alopecia areata following COVID-19 vaccine: a systematic review.European journal of medical research · 2024Pooled it
- New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies.Frontiers in medicine · 2024Pooled it
- A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.European journal of medical research · 2023Pooled it
- Morphea Triggered by COVID-19 Vaccination.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Unraveling COVID-19-vaccination-induced bullous pemphigoid: a case report and review of the literature.Journal of medical case reports · 2025Review
- Review
- New Onset of Hair Loss Disorders During the Coronavirus Disease 2019 Pandemic: A Korean Nationwide Population-Based Study.Annals of dermatology · 2025Article
- Cutaneous small vessel vasculitis in the COVID-19 era: a systematic review.Skin health and disease · 2025Review
- Adverse Cutaneous Reactions Following COVID-19 Vaccination Among Patients with Pre-Existing Urticaria: A Cross-Sectional Study at a Tertiary Care Center in Saudi Arabia.International journal of general medicine · 2025Article
- A scoping review of alopecia areata and its relationship to COVID-19 vaccinations.Archives of dermatological research · 2024Article
- Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review.Rheumatology international · 2024Review
- New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.Vaccines · 2024Review
- Pityriasis following COVID-19 vaccinations: a systematic review.Dermatology reports · 2024Article
- Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters.Vaccines · 2024Review
- New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination.SAGE open medical case reports · 2024Article
- COVID-19 vaccine-associated vasculitis: A systematic review.SAGE open medicine · 2024Review
- Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.Rheumatic diseases clinics of North America · 2023Review
- Review
- Generalized morphea induced by the COVID-19 vaccine in a patient with chronic urticaria.Dermatology reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID-19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID-19 vaccination were enrolled in our case-series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty-five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18-91) were enrolled in our study. Twenty-two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new-onset lichen planus (LP) and 1 (4%) patient manifested LP flare-up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new-onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare-up. Other new-onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID-19 vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.